Oral Calcitriol: A New Therapeutic Agent In Cutaneous Lichen Scerosis
February 2003 | Volume 2 | Issue 1 | Original Article | 28 | Copyright © February 2003
S. Ronger, MD; A.M .Villard, MD; F. Meunier-Mure, MD; B. Balme, MD and L. Thoma., MD
Observation: One patient with cutaneous generalized LS resistant to different therapeutics was treated with calcitriol in an oral daily dose of 0.5 mcg. After 6 months of treatment, the skin extensibility increased, and the lesions improved. The improvement persisted after discontinuation of therapy during a follow-up period of one year. The only side effect was hypercalciuria, which resolved with dose reduction.
Conclusion: Calcitriol has shown a beneficial effect in scleroderma and morphea during open studies. A case is reported of a patient with LS who had a dramatic response to calcitriol. Double blind, placebo-con trolled trials are needed to assess the therapeutic value of calcitriol in patients with LS.